(4-Chloro-benzyl)-quinazolin-4-yl-amine | 70137-93-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (4-Chloro-benzyl)-quinazolin-4-yl-amine
• 英文别名: N-[(4-chlorophenyl)methyl]quinazolin-4-amine
• CAS: 70137-93-8
• 化学式: C₁₅H₁₂ClN₃
• mdl: MFCD11849174
• 分子量: 269.733
• InChiKey: BTRLSAYDVSPYCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-chloro-N-(4-chlorobenzyl)quinazolin-4-amine 在 四甲基乙二胺 、 溶剂黄146 、 锌 、 2-巯基烟酸 作用下， 以 甲醇 为溶剂， 生成 (4-Chloro-benzyl)-quinazolin-4-yl-amine
  参考文献：
  名称：

  Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors

  摘要：

  Wnt 通路在发育和组织稳态中起着关键作用，由于它在许多癌症中的异常激活，抗癌药物的开发日益受到关注。在这项研究中，我们发现了一种新型小分子系列，其噻吩嘧啶支架可作为依赖β-catenin的Wnt通路的下游抑制剂。我们利用依赖 Wnt 的三阴性乳腺癌（TNBC）细胞系对这种新型化学类型进行了研究。通过结构活性关系（SAR）探索，发现了 5a、5d、5e 等低微摩尔化合物以及 9d 等具有喹唑啉支架的新型系列化合物。进一步的研究表明，这些化合物具有抑制 HCC1395 和 MDA-MB-468 TNBC 细胞系癌症存活的活性，而不会影响非癌症乳腺上皮细胞系 MCF10a。这种抗增殖作用与多西他赛治疗具有协同作用。总之，我们发现了可作为依赖于β-catenin的Wnt通路下游抑制剂的新型化学类型，它们可以扩大治疗TNBC的选择范围。

  DOI：

  10.3389/fphar.2022.1045102

文献信息

• [EN] PRODUCTION OF INDUCED PLURIPOTENT STEM CELLS<br/>[FR] PRODUCTION DE CELLULES SOUCHES PLURIPOTENTES INDUITES
  申请人：HARVARD COLLEGE

  公开号：WO2012079079A1

  公开（公告）日：2012-06-14

  The present disclosure relates to methods and compositions that improve the in vitro production of induced pluripotent stem cells through the use of compounds that promote degradation of p53. The disclosure also relates to compositions and methods for the treatment of cancer, pancreatitis and intracellular pathogens.

  本公开涉及通过促进p53降解的化合物来改善诱导多能干细胞的体外生产的方法和组合物。该公开还涉及用于治疗癌症、胰腺炎和细胞内病原体的组合物和方法。
• Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.
  作者：Gordon W. Rewcastle、William A. Denny、Alexander J. Bridges、Hairong Zhou、Donna R. Cody、Amy McMichael、David W. Fry

  DOI：10.1021/jm00018a008

  日期：1995.9

  A series of 4-substituted quinazolines and related compounds have been prepared and evaluated for their ability to inhibit the tyrosine kinase activity of the epidermal growth factor receptor on a phospholipase C-gamma 1-derived substrate. The results show a narrow structure-activity relationship (SAR) for the basic ring system, with quinazoline being the preferred chromophore and benzylamino and anilino

  已经制备了一系列的4-取代的喹唑啉和相关化合物，并评估了它们在磷脂酶C-γ1衍生的底物上抑制表皮生长因子受体的酪氨酸激酶活性的能力。结果表明基本环系统的结构-活性关系（SAR）狭窄，喹唑啉是优选的生色团，苄基氨基和苯胺基是优选的侧链。在4-苯胺基系列中，苯环的3-位被小的亲脂性吸电子基团取代提供了具有增强效价的类似物。研究了两个系列的化合物[4-（苯甲基）氨基和4-（3-溴苯基）氨基]，以确定喹唑啉取代基的SAR。在更具活性的4-（3-溴苯基）氨基系列中，给电子基团（NH2，OMe）在6或7位的活性增加，其模式与对喹唑啉环的8位附近的高电子密度的要求一致。6,7-二甲氧基衍生物是这两个系列中最有效的，而4-（3-溴苯基）氨基衍生物（3）的IC50为0.029 nM，是迄今为止最有效的酪氨酸激酶活性抑制剂。表皮生长因子受体酶的作用。
• Discovery of quinazolines as a novel structural class of potent inhibitors of NF-κB activation
  作者：Masanori Tobe、Yoshiaki Isobe、Hideyuki Tomizawa、Takahiro Nagasaki、Hirotada Takahashi、Tominaga Fukazawa、Hideya Hayashi

  DOI：10.1016/s0968-0896(02)00440-6

  日期：2003.2

  We disclose here a new structural class of low-molecular-weight inhibitors of NF-kappaB activation that were designed and synthesized by starting from quinazoline derivative 6a. Structure-activity relationship (SAR) studies based on 6a elucidated the structural requirements essential for the inhibitory activity toward NF-kappaB transcriptional activation, and led to the identification of the 6-amino-4-phenethylaminoquinazoline skeleton as the basic framework. In this series of compounds, 11q, containing the 4-phenoxyphenethyl moiety at the C(4)-position, showed strong inhibitory effects on both NF-kappaB transcriptional activation and TNF-alpha production. Furthermore, 11q exhibited an anti-inflammatory effect on carrageenin-induced paw edema in rats. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Potent Small Molecule Inhibitors of Autophagy, and Methods of Use Thereof
  申请人：Yuan Junying

  公开号：US20120258975A1

  公开（公告）日：2012-10-11

  Certain aspects of the invention relates to small molecule autophagy inhibitors of the formula (I), and their use for treatment and prevention of cancers and acute pancreatitis. As disclosed herein, a small molecule inhibitor of autophagy was been identified from an image-based screen in a known bioactive library. It was found that this autophagy inhibitor functions by promoting the degradation of type III PI3 kinase complex which is required for initiating autophagy. Medicinal chemistry studies led to small molecular autophagy inhibitors with improved potency and selectivity. (I)
• [EN] POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF<br/>[FR] PETITES MOLÉCULES DOTÉES D'UNE PUISSANTE ACTIVITÉ INHIBITRICE DE L'AUTOPHAGIE, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：HARVARD COLLEGE

  公开号：WO2011011522A2

  公开（公告）日：2011-01-27

  Certain aspects of the invention relates to small molecule autophagy inhibitors of the formula (I), and their use for treatment and prevention of cancers and acute pancreatitis. As disclosed herein, a small molecule inhibitor of autophagy was been identified from an image-based screen in a known bioactive library. It was found that this autophagy inhibitor functions by promoting the degradation of type III PI3 kinase complex which is required for initiating autophagy. Medicinal chemistry studies led to small molecular autophagy inhibitors with improved potency and selectivity. (I)